Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

Wendlinger, Simone; Wohlfarth, Jonas; Kreft, Sophia; Siedel, Claudia; Kilian, Teresa; Dischinger, Ulrich; Heppt, Markus V.; Wistuba‐Hamprecht, Kilian; Meier, Friedegund; Goebeler, Matthias; Schadendorf, Dirk; Gesierich, Anja; Kosnopfel, Corinna; Schilling, Bastian

doi:10.3390/cancers14092294

Cited by 9 publications

(6 citation statements)

References 78 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between eosinophils and tumors can be traced back to 1893 ( 69 ). An increase in tumor-related eosinophils was found in tumor tissues.…”

Section: Eosinophil-related Diseasesmentioning

confidence: 99%

Recent advances of eosinophils and its correlated diseases

Zhang¹,

Zhu

Zhang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Eosinophils are differentiated by bone marrow multipotent progenitor cells and are further released into peripheral blood after maturation. Human eosinophils can exhibit unique multi-leaf nuclear morphology, which are filled with cytoplasmic granules that contain cytotoxicity and immune regulatory proteins. In recent years, many studies focused on the origin, differentiation and development process of eosinophils. It has been discovered that the eosinophils have the regulatory functions of innate and adaptive immunity, and can also function in several diseases, including asthma, chronic obstructive pulmonary diseases, acute respiratory distress syndrome, malignant tumors and so on. Hence, the role and effects of eosinophils in various diseases are emphasized. In this review, we comprehensively summarized the development and differentiation process of eosinophils, the research progress of their related cytokines, diseases and current clinical treatment options, and discussed the potential drug target, aiming to provide a theoretical and practical basis for the clinical prevention and treatment of eosinophil-related diseases, especially respiratory diseases. To conclude, the guiding significance of future disease treatment is proposed based on the recent updated understandings into the cell functions of eosinophils.

show abstract

“…The relationship between eosinophils and tumors can be traced back to 1893 ( 69 ). An increase in tumor-related eosinophils was found in tumor tissues.…”

Section: Eosinophil-related Diseasesmentioning

confidence: 99%

Recent advances of eosinophils and its correlated diseases

Zhang¹,

Zhu

Zhang

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Wendlinger et al. ( 21 ) demonstrated that high pre-treatment eosinophil counts in patients with advanced melanoma were associated with a significantly improved response to MAPK signaling pathway inhibitors (MAPKi). Functionally, eosinophils have potent cytotoxicity against melanoma cells that can be enhanced by MAPKi ( 21 ).…”

Section: Resultsmentioning

confidence: 99%

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand,

Hunger,

Seyed Jafari

2024

Front. Oncol.

View full text Add to dashboard Cite

The importance of eosinophilic granulocytes in cancer has been widely discussed in recent years. The current study reviews the evidence on the role of eosinophilic granulocytes in melanoma as a prognostic marker for cancer progression and the efficacy of treatment with modern immune checkpoint inhibitors. A total of 33 human clinical studies were included in the review, with heterogeneous data due to differences in patients populations, study design and inclusion of small study groups. However, 28 of the 33 studies suggested that eosinophilic granulocytes could be used as a prognostic biomarker for outcome and/or potential response to systemic treatment and/or occurrence of adverse events in melanoma patients. Nevertheless, the exact role of eosinophils remains to be elucidated. Further prospective, larger and better controlled studies are warranted to clarify the significance of eosinophilic granulocytes in patients with melanoma, in more details.

show abstract

“…34,35 The anticancer effect of eosinophils has been previously observed, 36,37 including in melanoma, where both increased circulating and intratumoral eosinophils predicted improved responses to immunotherapy. [38][39][40][41] The mechanism through which eosinophils exert anti-tumor functions is not well understood. In a murine melanoma model, a prior study found that IL-33 stimulated recruitment of eosinophils to the lungs and significantly delayed development of pulmonary metastasis.…”

Section: Discussionmentioning

confidence: 99%

Atopy improves survival and decreases risk of brain metastasis in cutaneous melanoma

Neff,

Price,

Cioffi

et al. 2024

Preprint

View full text Add to dashboard Cite

Importance: Development of new therapies in melanoma has increased survival, and as a result more patients are living to develop brain metastasis (BrM). Identifying patients at increased risk of BrM is therefore of significant public health importance. Objective: To determine whether history of atopy is associated with improved survival or reduced incidence of BrM in cutaneous melanoma. Design: A retrospective cohort study conducted from June 2022 to March 2024. Setting: Population-based in states with Surveillance, Epidemiology and End Results (SEER) supported cancer registries. Participants: Individuals (≥65 years) diagnosed with cutaneous melanoma between January 1, 2008 and December 31, 2017 that are participants in traditional Medicare. Exposure(s): Individuals were compared that had history of atopy (allergic rhinitis, atopic dermatitis, asthma, and/or allergic/atopic conjunctivitis) diagnosed prior to melanoma diagnosis, ascertained using ICD-9 or ICD-10 codes in Medicare claims. Main Outcome(s) and Measure(s): Primary endpoints were diagnosis with a BrM or death during the follow-up period. Associations between atopy and endpoints were assessed using cox proportional hazards models to estimate hazard ratios (HR) and p-values. Results: A total of 29,956 cutaneous melanoma cases were identified (median age 76, 60% male and 97% non-Hispanic White). Overall, 7.1% developed BrM during follow up. Among the 35% that had history of atopy, the most common condition was atopic dermatitis (19%). After adjustment for demographic and prognostic factors, atopy was associated with a 16% decrease in death (HR=0.84 [95%CI:0.80-0.87], pFDR<0.001). Among those with non-metastatic disease at time of diagnosis, atopy conferred a 15% decrease in cumulative incidence BrM (HR=0.85 [95%CI: 0.76-0.94], pFDR=0.006), with a 25% decrease associated with atopic dermatitis (HR=0.75 [95%CI:0.65-0.86], pFDR<0.001). Among those with metastatic disease at diagnosis (any metastatic site), only those who received immune checkpoint inhibitors had a survival benefit associated with atopy (HR=0.31, [95%CI:0.15-0.64], p=0.001 vs HR=1.41, [95%CI:0.87- 2.27], p=0.165). Conclusions and Relevance: Atopy, particularly atopic dermatitis, was significantly associated with improved survival and decreased incidence of BrM. The improved survival associated with these conditions in the context of immunotherapy suggests that these conditions in the elderly may identify those with more robust immune function that may be more responsive to treatment.

show abstract

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

Cited by 9 publications

References 78 publications

Recent advances of eosinophils and its correlated diseases

Recent advances of eosinophils and its correlated diseases

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Atopy improves survival and decreases risk of brain metastasis in cutaneous melanoma

Contact Info

Product

Resources

About